Hangzhou Dessight Biomedical has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. This significant capital injection was led by Linear Venture, with GL Ventures also participating. The funds will be directed towards market filing for an ophthalmic surgery robot, the development of microsurgery robots, and team expansion.
Use of Proceeds
The proceeds from this financing round will be used to advance Dessight Biomedical’s ophthalmic surgery robot towards market approval. Additionally, the company will invest in the development of its microsurgery robot technology and expand its team to support these growth initiatives.
Company Background and Product Development
Founded in 2021, Dessight Biomedical is focused on developing an ophthalmic surgery robot. This innovative device is currently being prepared for regulatory trials and is being explored for use in indications such as cataracts and glaucoma. The development of this robot represents a significant advancement in ophthalmic surgery, aiming to enhance surgical precision and improve patient outcomes.-Fineline Info & Tech
